WB result of CFB Rabbit Polyclonal Antibody
Primary antibody: CFB Rabbit Polyclonal Antibody at 1/1000 dilution
Lane 1: Human serum lysate 20 μg
Lane 2: Human plasma lysate 20 μg
Secondary antibody: Goat Anti-Rabbit IgG (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 86 kDa
Observed MW: 105 kDa
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | CFB |
| Synonyms | Complement factor B; C3/C5 convertase; Glycine-rich beta glycoprotein (GBG); PBF2; Properdin factor B; BF; BFD |
| Immunogen | Recombinant Protein |
| Location | Secreted |
| Accession | P00751 |
| Antibody Type | Polyclonal antibody |
| Isotype | IgG |
| Application | WB |
| Reactivity | Hu, Ms, Rt |
| Positive Sample | Human serum, Human plasma, mouse plasma, rat plasma |
| Predicted Reactivity | Or, Cz, Gor |
| Purification | Protein A |
| Concentration | 0.5 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 40% Glycerol, 0.05% BSA, 0.02% sodium azide |
| Stability & Storage | 12 months from date of receipt / reconstitution, -20 °C as supplied |
Dilution
| application | dilution | species |
| WB | 1:1000 | Hu, Ms, Rt |
Background
Complement factor B (CFB) is the core serine protease of the alternative complement pathway, encoded by the CFB gene located in the MHC class III region on human chromosome 6, and secreted into plasma as a single-chain zymogen of approximately 90 kDa. Its structure comprises three modules: three N-terminal complement control protein domains, a central von Willebrand factor A (VWA) domain, and a C-terminal serine protease domain; in the zymogen state, the classical activation helix of the VWA domain is replaced by a helix from the preceding linker region, safely locking the cleavage site in an inactive conformation. When the alternative pathway is initiated, CFB binds to C3b deposited on pathogen surfaces, triggering displacement of the N-terminal control domains and rearrangement of the central double helix, which exposes the site cleaved by factor D; cleavage releases the Ba fragment, and the remaining Bb fragment together with C3b forms the alternative pathway C3 convertase (C3bBb), thereby amplifying the complement cascade. At the pathological level, gain-of-function mutations in CFB can increase the stability of the C3 convertase or confer resistance to regulation by factor H, representing one of the pathogenic mechanisms of complement-mediated hemolytic uremic syndrome (CM-HUS); whereas biallelic loss-of-function mutations cause CFB deficiency, manifesting as recurrent susceptibility to encapsulated bacteria (such as Streptococcus pneumoniae and Neisseria meningitidis). Given the pivotal position of CFB in the amplification loop of the alternative pathway, its small-molecule inhibitors (such as iptacopan, which has entered phase III clinical trials, and subsequent drug candidates) have become an important strategic direction for the treatment of complement-mediated diseases including paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, and age-related macular degeneration.
Picture
Picture
Western Blot
WB result of CFB Rabbit Polyclonal Antibody
Primary antibody: CFB Rabbit Polyclonal Antibody at 1/1000 dilution
Lane 1: mouse plasma lysate 20 μg
Secondary antibody: Goat Anti-Rabbit IgG (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 86 kDa
Observed MW: 105 kDa
WB result of CFB Rabbit Polyclonal Antibody
Primary antibody: CFB Rabbit Polyclonal Antibody at 1/1000 dilution
Lane 1: rat plasma lysate 20 μg
Secondary antibody: Goat Anti-Rabbit IgG (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 86 kDa
Observed MW: 105 kDa
